Medical management of acute heart failure.

Faculty reviews Pub Date : 2021-12-06 eCollection Date: 2021-01-01 DOI:10.12703/r/10-82
Hayaan Kamran, W H Wilson Tang
{"title":"Medical management of acute heart failure.","authors":"Hayaan Kamran,&nbsp;W H Wilson Tang","doi":"10.12703/r/10-82","DOIUrl":null,"url":null,"abstract":"<p><p>Despite recent advances in the treatment of chronic heart failure, therapeutic options for acute heart failure (AHF) remain limited. AHF admissions are associated with significant multi-organ dysfunction, especially worsening renal failure, which results in significant morbidity and mortality. There are several aspects of AHF management: diagnosis, decongestion, vasoactive therapy, goal-directed medical therapy initiation and safe transition of care. Effective diagnosis and prognostication could be very helpful in an acute setting and rely upon biomarker evaluation with noninvasive assessment of fluid status. Decongestive strategies could be tailored to include pharmaceutical options along with consideration of utilizing ultrafiltration for refractory hypervolemia. Vasoactive agents to augment cardiac function have been evaluated in patients with AHF but have shown to only have limited efficacy. Post stabilization, initiation of quadruple goal-directed medical therapy-angiotensin receptor-neprilysin inhibitors, mineral receptor antagonists, sodium glucose type 2 (SGLT-2) inhibitors, and beta blockers-to prevent myocardial remodeling is being advocated as a standard of care. Safe transition of care is needed prior to discharge to prevent heart failure rehospitalization and mortality. Post-discharge close ambulatory monitoring (including remote hemodynamic monitoring), virtual visits, and rehabilitation are some of the strategies to consider. We hereby review the contemporary approach in AHF diagnosis and management.</p>","PeriodicalId":73016,"journal":{"name":"Faculty reviews","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725647/pdf/","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Faculty reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.12703/r/10-82","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6

Abstract

Despite recent advances in the treatment of chronic heart failure, therapeutic options for acute heart failure (AHF) remain limited. AHF admissions are associated with significant multi-organ dysfunction, especially worsening renal failure, which results in significant morbidity and mortality. There are several aspects of AHF management: diagnosis, decongestion, vasoactive therapy, goal-directed medical therapy initiation and safe transition of care. Effective diagnosis and prognostication could be very helpful in an acute setting and rely upon biomarker evaluation with noninvasive assessment of fluid status. Decongestive strategies could be tailored to include pharmaceutical options along with consideration of utilizing ultrafiltration for refractory hypervolemia. Vasoactive agents to augment cardiac function have been evaluated in patients with AHF but have shown to only have limited efficacy. Post stabilization, initiation of quadruple goal-directed medical therapy-angiotensin receptor-neprilysin inhibitors, mineral receptor antagonists, sodium glucose type 2 (SGLT-2) inhibitors, and beta blockers-to prevent myocardial remodeling is being advocated as a standard of care. Safe transition of care is needed prior to discharge to prevent heart failure rehospitalization and mortality. Post-discharge close ambulatory monitoring (including remote hemodynamic monitoring), virtual visits, and rehabilitation are some of the strategies to consider. We hereby review the contemporary approach in AHF diagnosis and management.

Abstract Image

Abstract Image

Abstract Image

急性心力衰竭的医疗管理。
尽管最近在慢性心力衰竭治疗方面取得了进展,但急性心力衰竭(AHF)的治疗选择仍然有限。AHF入院与明显的多器官功能障碍有关,特别是肾功能衰竭恶化,导致显著的发病率和死亡率。AHF管理有几个方面:诊断、去充血、血管活性治疗、目标导向的药物治疗开始和护理的安全过渡。有效的诊断和预测在急性情况下非常有帮助,并依赖于生物标志物评估和无创液体状态评估。减充血性策略可以量身定制,包括药物选择以及考虑利用超滤治疗难治性高血容量。血管活性药物增强心功能已在AHF患者中进行了评估,但仅显示出有限的疗效。稳定后,开始四种目标导向的药物治疗-血管紧张素受体-neprilysin抑制剂,矿物质受体拮抗剂,2型葡萄糖钠(SGLT-2)抑制剂和β受体阻滞剂-预防心肌重构被提倡作为一种标准护理。出院前需要安全过渡护理,以防止心力衰竭再住院和死亡。出院后密切的门诊监测(包括远程血流动力学监测),虚拟访问和康复是一些需要考虑的策略。我们在此回顾AHF诊断和管理的当代方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信